Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

pasireotide 4Temozolomide 2lutetium Lu 177 dotatate 1farletuzumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tranexamic Acid 1Thyrotropin-Releasing Hormone 1TBR-760 1Rosiglitazone 1Nivolumab 1Microarray Analysis 1Lapatinib 1Ipilimumab 1DNA Methylation 1Complementary Therapies 1Capecitabine 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pituitary Neoplasms × Ipilimumab × Clear all
NCT04042753 2026-05-14

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
9 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡